Non-Hodgkin Lymphoma News
- ASH 2019In Follicular Lymphoma, Can MRD Predict Relapse or Define Cure?
- ASH 2019Study Halted; 'Hyperprogression' Seen With Nivolumab for R/R PTCL
- ASH 2019Allogeneic Transplant Best in Follicular Lymphoma, but Worth It?
- ASH 2019Some Patients with DLBCL Can Skip Radiation: 'It's a Win'
- ASH 2019An Off-the-Shelf Drug to Rival CAR T Cells: 'Very Exciting'
- ASH 2019'Real-World' Data Show CAR-T Therapies Are Cost Effective
- ASH 2019The Next 'Big Thing' for Blood Cancers Featured at ASH 2019
- Novartis's $90 Mln Swiss Factory to Help Solve Cell Therapy Bottleneck
- Patients With Cancer at Increased Risk for Cardiovascular Death
- Morphosys to Boost Size of Tafasitamab Drug Trial on Encouraging Interim Data
- After Backlash, Teva Will Resume Production of Vincristine
- 'Real Crisis': Ruinous Out-of-Pocket Costs for Blood Cancers
- Newly Diagnosed Hodgkin Lymphoma Can Be Safely Managed During Pregnancy
- Novel Combination Strategy Active in Poor-Risk AML
- Second Primaries Different in Early- vs Late-Stage DLBCL
- Change the 'Asymptomatic' Label for Rare Lymphoma Status
- Childhood BCG Vaccination May Curb Lung Cancer Later
- Family Members at Higher Risk for Blood Cancers
- Germany to Ban Use of Glyphosate From End of 2023
- HIV: Underlying Infection Still Drives Deaths in US